Introduction
Diabetes is a metabolic disease in which consist of elevated blood glucose levels over a prolonged period. It is caused due to either pancreas not able to produce enough insulin or cells of the body not responding to the insulin produced. Insulin management system helps to deliver the insulin to the body of the patient. A number of different types of insulin delivery products are available in the market which includes insulin pen injectors, needle and syringe, insulin jet injectors, implantable pumps, external insulin pumps, insulin patches, and others.
Market Dynamics
The major driving factor for the market is increasing prevalence of the diabetes. According to the report published by the WHO, in 2014, approximately 422 million people across the globe were suffering from diabetes. Additionally, obesity and smoking are the major factors for the increasing the diabetic population. Increasing number of people suffering from obesity and adoption of smoking by people have fueled the growth of the market. Moreover, increased the demand for the better treatment option, increasing healthcare expenditure, increasing government support and advancement in the technology have boosted the growth of the market during the forecast period 2018—2026.However, high costs of syringes, lack of awareness among the people is the major factors hindering the growth of the market.
In near future the market is expecting a healthy opportunity owing to the continuous increasing demand for the better and better products.
Market Classification and Overview
The global insulin management system market is majorly segmented into product type, mode of action, diabetes type, and end users.
On the basis of product type, the market is segmented into Insulin pen injectors, needle and syringe, insulin jet injectors, implantable pumps, external insulin pumps, insulin patches, and others
On the basis of mode of action, the market is segmented into short acting insulin, intermediate acting insulin, rapid acting insulin, pre-mixed insulin.
On the basis of diabetes type, the market is segmented into type-I diabetes, type-IIdiabetes.
On the basis of end users, the market is segmented into hospital & clinics, ambulatory centre, and other.
Regional Overview
Globally, the insulin management system market is segmented into North America, Europe, Asia Pacific and Latin America, Middle East & Africa.
North America is expected to dominate the insulin management system market owing to their advancement in technology, huge diabetic population and high healthcare spending. Additionally, increasing government support and presence of a huge number of players will support the growth of the market.
Europe accounts for the second leading market in the forecast period followed by the Asia Pacific. Well developed economies and huge government support in this region have driven the growth of the market.Asia Pacific region is expected to have the fastest growth during the forecast period owing to huge number of diabetic and obese population of the region. According to the International Diabetes Federation (IDF), over 60% of total global diabetic population is in Asia Pacific of which over 114 million are present in China. Additionally, increasing per capita income and increasing government support have fueled the growth of the market. LAMEA region is expected to show healthy growth during the forecast period 2018—2026. Increasing per capita income and presence of huge untapped opportunities is driving the growth of the market. Additionally, lack of medical facilities Africa region creates an opportunity for key players to expand the market in this region.
Report Coverage
Market |
Insulin Management System Market |
Analysis Period |
2015 – 2026 |
Historic Data |
2015 – 2016 |
Base Year |
2017 |
Forecast Data |
2018 – 2026 |
Market Stratification |
Product Type, Mode of Action, Diabetes Type, End Users, Geography |
Regional Scope |
North America, Europe, Asia-Pacific, Latin America, Middle East and Africa (MEA) |
Report Coverage |
Market Trends, Drivers, Restraints, Porter's Five Forces Analysis, Competitive Analysis, Player Profiling, Value Chain Analysis |
Market Participants
Some of the major key players in the market are Abbott, Accu-Chek, Eli Lilly, Bayer, Animas, DexCom, Medtronic, Roche, LifeScan, Novo Nordisk, Merck, Novartis, Sanofi-aventis, Takeda Pharmaceuticals, and Bristol-Myers Squibb.
Market Segmentation
Market By Product Type
Market By Mode of Action
Market By Diabetes Type
Market By End User
Market By Geography